摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-Tert-butyl-1-methylpiperidin-1-ium

中文名称
——
中文别名
——
英文名称
1-Tert-butyl-1-methylpiperidin-1-ium
英文别名
——
1-Tert-butyl-1-methylpiperidin-1-ium化学式
CAS
——
化学式
C10H22N+
mdl
——
分子量
156.29
InChiKey
IZLKOHKCJXJRLV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    11
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    0
  • 氢给体数:
    0
  • 氢受体数:
    0

文献信息

  • BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF GASTROINTESTINAL INFECTIONS
    申请人:Lumena Pharmaceuticals, Inc.
    公开号:US20150119345A1
    公开(公告)日:2015-04-30
    Provided herein are methods for treating or preventing gastrointestinal and/or liver infections utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents and/or FXR agonists. Also provided herein are methods for increasing the levels of an enteroendocrine peptide or hormone in an individual suffering from a gastrointestinal infection or liver infection utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents and/or FXR agonists.
    本文提供了利用胆汁酸转运抑制剂和/或肠内分泌肽增强剂和/或FXR激动剂治疗或预防胃肠和/或肝感染的方法。本文还提供了利用胆汁酸转运抑制剂和/或肠内分泌肽增强剂和/或FXR激动剂增加患有胃肠感染或肝感染的个体体内肠内分泌肽或激素水平的方法。
  • Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease
    申请人:Lumena Pharmaceuticals, Inc.
    公开号:US20130108573A1
    公开(公告)日:2013-05-02
    Provided herein are methods of treating or ameliorating hypercholemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof.
    本文提供了一种治疗或改善高胆固醇血症或胆汁淤积性肝病的方法,即通过向需要的个体施用治疗有效量的顶端钠依赖性胆酸转运蛋白抑制剂(ASBTI)或其药用可接受盐。还提供了一种治疗或改善肝病、降低血清胆酸或肝内胆酸水平、治疗或改善瘙痒、降低肝酶或减少胆红素的方法,即通过向需要的个体施用治疗有效量的ASBTI或其药用可接受盐。
  • Use of an ionic liquid for storing hydrogen
    申请人:VTU Holding GmbH
    公开号:EP2623457A1
    公开(公告)日:2013-08-07
    Method of storing hydrogen by forming a first ionic liquid by inducing a borohydride in a second ionic liquid comprising a cation and an anion comprising borate, and forming the second ionic liquid by releasing the hydrogen out of the first ionic liquid by using water and/or a catalyst, which method is characterized in that the first and the second ionic liquid are both water miscible and the second ionic liquid is separated, particularly is salted out, from solution in water by adding a separation inducer; certain ionic liquids for storing and releasing hydrogen comprising a borohydride or for preparing a ionic liquid for storing and releasing hydrogen comprising a borate; and a process for preparing ionic liquids for storing and releasing hydrogen comprising a borohydride.
    通过在包含阳离子和包含硼酸盐的阴离子的第二离子液体中引入硼氢化物形成第一离子液体的方法来存储氢气,并通过使用水和/或催化剂从第一离子液体释放氢气形成第二离子液体,该方法的特征在于第一和第二离子液体均与水相溶,并且通过添加分离诱导剂从水溶液中分离第二离子液体,特别是通过盐析;某些用于存储和释放氢气的离子液体,包括硼氢化物,或用于制备含硼酸盐的存储和释放氢气的离子液体;以及用于制备含硼氢化物的存储和释放氢气的离子液体的过程。
  • BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF OBESITY AND DIABETES
    申请人:Young Andrew A.
    公开号:US20120157399A1
    公开(公告)日:2012-06-21
    Provided herein are methods of utilizing bile acid transport inhibitors for the treatment of obesity and diabetes.
    本文提供了利用胆汁酸转运抑制剂治疗肥胖症和糖尿病的方法。
  • BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS
    申请人:Gedulin Bronislava
    公开号:US20130059807A1
    公开(公告)日:2013-03-07
    Provided herein are methods of utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents for the treatment of obesity, diabetes, and inflammatory gastrointestinal conditions.
    本文提供了一种利用胆汁酸转运抑制剂和/或肠内分泌肽增强剂治疗肥胖症、糖尿病和炎症性肠道疾病的方法。
查看更多